drugset / Trial / NCT04313608
A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma
Non-randomizedSequentialOpen-labelTreatment
Summary
This study is designed to evaluate the safety and efficacy of glofitamab or mosunetuzumab in combination with gemcitabine and oxaliplatin (Glofit-GemOx or Mosun-GemOx) in participants with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBCL).
Timeline
- Start
- 2020-06-04
- Primary completion
- 2021-10-26
- Completion
- 2021-10-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Glofitamab | Monoclonal antibody | — | Intravenous |
| Subject | Mosunetuzumab | Monoclonal antibody | — | Intravenous |
| Background | Gemcitabine | Small molecule | — | Intravenous |
| Background | Obinutuzumab | Monoclonal antibody | — | Intravenous |
| Background | Oxaliplatin | Small molecule | — | Intravenous |
| Background | Tocilizumab | Monoclonal antibody | — | Intravenous |